Allergan in buyout talks with Actavis: CNBC
ALLERGAN (AGN.NY)has questioned the sustainability of Valeant's growth and business model and "opaque" financial disclosures.
Valeant said on Wednesday that such concerns were "completely unfounded."
"In the third quarter, we expect our results to be better than consensus on revenue, and better than the guidance we provided in our second quarter earnings call for Cash EPS, organic growth, restructuring charges and adjusted cash flow from operations," Valeant Chief Executive Michael Pearson said in a letter to Allergan's board.
(Reporting by Vidya L Nathan; Editing by Saumyadeb Chakrabarty)